NewEdge Wealth LLC Takes $95.26 Million Position in Gilead Sciences, Inc. $GILD

NewEdge Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 754,019 shares of the biopharmaceutical company’s stock, valued at approximately $95,263,000. Gilead Sciences accounts for about 1.0% of NewEdge Wealth LLC’s portfolio, making the stock its 19th largest position. NewEdge Wealth LLC owned 0.06% of Gilead Sciences as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Persistent Asset Partners Ltd acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth $25,000. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at about $26,000. Finally, Wealth Preservation Advisors LLC increased its stake in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the transaction, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the sale, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at approximately $22,918,780.56. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 82,000 shares of company stock worth $10,837,860 over the last 90 days. Company insiders own 0.30% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating on Gilead, supporting the bullish view that the company’s recent momentum can continue. BMO Capital reaffirms Buy rating
• Positive Sentiment: Zacks Research raised estimates for third-quarter 2026 EPS to $1.93 from $1.84, fourth-quarter 2026 EPS to $2.14 from $2.07, and full-year 2027 EPS to $9.30 from $9.11. It also lifted estimates for parts of 2027, indicating improving expectations for near-term earnings. Gilead Sciences analyst estimates
• Positive Sentiment: Investors remain focused on Gilead’s expanding HIV portfolio. Biktarvy continues to anchor sales, while Yeztugo and additional pipeline programs could create new treatment and prevention opportunities. The company’s latest reported revenue also increased 10.6% year over year to $7.8 billion, exceeding expectations. Gilead’s expanding HIV portfolio
• Positive Sentiment: Gilead’s quarterly dividend of $0.82, equivalent to $3.28 annually, provides ongoing income support and reinforces its appeal to defensive and healthcare-focused investors.
• Neutral Sentiment: Zacks reduced estimates for first-quarter 2028 EPS to $2.14 from $2.21, second-quarter 2028 EPS to $2.27 from $2.33, and full-year 2028 EPS to $9.58 from $10.00. These cuts temper the otherwise positive near-term revisions and suggest some uncertainty about longer-term growth.
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares, while CFO Andrew Dickinson sold 3,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may modestly weigh on sentiment.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $147.60 on Thursday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The company has a market capitalization of $183.02 billion, a price-to-earnings ratio of -55.28 and a beta of 0.32. The business has a 50-day moving average of $131.21 and a 200-day moving average of $136.51.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company’s revenue was up 10.6% on a year-over-year basis. During the same period last year, the business posted $2.01 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Analyst Ratings Changes

Several research firms have recently weighed in on GILD. Rothschild & Co Redburn reduced their price objective on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Barclays dropped their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Needham & Company LLC restated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Morgan Stanley reduced their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research report on Monday, July 27th. Finally, Truist Financial decreased their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.